ECT-Lithium Combination is Associated With Less Cognitive Impairment in Bipolar Depression Compared to Unipolar: Could This Also Support the Biological Difference Between the 2 Types of Depression?

2021 ◽  
Vol 89 (9) ◽  
pp. S203
Author(s):  
Nagy Youssef ◽  
Rikinkumar Patel
Keyword(s):  
Cognitive Impairment ◽  
Bipolar Depression ◽  
Biological Difference

scholarly journals Using network analysis to explore cognitive domains in patients with unipolar versus bipolar depression: a prospective naturalistic study

CNS Spectrums ◽  
2019 ◽  
Vol 25 (3) ◽  
pp. 380-391 ◽  
Author(s):  
Cesare Galimberti ◽  
Monica Francesca Bosi ◽  
Valentina Caricasole ◽  
Riccardo Zanello ◽  
Bernardo Dell’Osso ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Network Analysis ◽  
Cognitive Performance ◽  
Bipolar Depression ◽  
Correlation Coefficients ◽  
Unipolar Depression ◽  
Executive Dysfunction ◽  
Network Graph ◽  
Significant Difference ◽  
Neurocognitive Profiles

Objective.Despite growing evidence in the field of cognitive function in mood disorders, the neurocognitive profiles of patients with unipolar and bipolar depression still need further characterization. In this study, we applied network analysis, hypothesizing this approach could highlight differences between major depressive disorder (MDD) and bipolar disorder (BD) from a cognitive perspective.Methods.The cognitive performance of 109 patients (72 unipolar and 37 bipolar depressed outpatients) was assessed through the Montreal Cognitive Assessment (MoCA), and a series of clinical variables were collected. Differences in cognitive performance between MDD and BD patients were tested using non-parametric tests. Moreover, a network graph representing MoCA domains as nodes and Spearman’s rho correlation coefficients between the domains as edges was constructed for each group.Results.The presence of mild cognitive impairment was observed in both MDD and BD patients during depression. No statistical significant difference was found between the two groups in terms of overall cognitive performance and across single domains. Nonetheless, network analytic metrics demonstrated different roles of memory and executive dysfunction in MDD versus BD patients: in particular, MDD network was more densely interconnected than BD network, and memory was the node with the highest betweenness and closeness centrality in MDD, while executive function was more central in BD.Conclusions.From a network analytic perspective, memory impairment displays a central role in the cognitive impairment of patients with unipolar depression, whereas executive dysfunction appears to be more central in bipolar depression. Further research is warranted to confirm our results.

scholarly journals Multidimensional cognitive impairment in unipolar and bipolar depression and the moderator effect of adverse childhood experiences

2017 ◽  
Vol 71 (5) ◽  
pp. 309-317 ◽  
Author(s):  
Sara Poletti ◽  
Veronica Aggio ◽  
Silvia Brioschi ◽  
Sara Dallaspezia ◽  
Cristina Colombo ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Adverse Childhood Experiences ◽  
Bipolar Depression ◽  
Childhood Experiences ◽  
Moderator Effect ◽  
Adverse Childhood

scholarly journals F89. COGNITIVE IMPAIRMENT WORSENING ACROSS AFFECTIVE TO PSYCHOSIS SPECTRUM: A COHORT STUDY OF UNIPOLAR/BIPOLAR DEPRESSION AND BIPOLAR SCHIZOAFFECTIVE DISORDERS

2018 ◽  
Vol 44 (suppl_1) ◽  
pp. S254-S254
Author(s):  
Martin Roy ◽  
Marie-Pierre Strippoli ◽  
Caroline Vandeleur ◽  
Elsa Gilbert ◽  
Enrique Castelao ◽  
...  
Keyword(s):  
Cohort Study ◽  
Cognitive Impairment ◽  
Bipolar Depression ◽  
Schizoaffective Disorders

scholarly journals Modafinil in the treatment of selected mental disorders

2021 ◽  
Vol 21 (3) ◽  
pp. 204-212
Author(s):  
Wacław Dyrda ◽  
Daria Smułek ◽  
Adam Wichniak ◽  
Keyword(s):  
Cognitive Impairment ◽  
Mental Disorders ◽  
Negative Symptoms ◽  
Depressive Disorders ◽  
Bipolar Depression ◽  
Sleep Apnoea ◽  
Psychotic Symptoms ◽  
Manic Symptoms ◽  
Obstructive Sleep ◽  
Increased Risk

Modafinil belongs to a class of wakefulness promoting agents. It is widely used in the treatment of sleep disorders. Although narcolepsy is the main indication for its use, hypersomnia from obstructive sleep apnoea and shift work sleep disorder are also indications in some countries. Due to its efficacy in the treatment of hypersomnia, the drug has also been clinically assessed in patients with mental disorders to reduce the severity of symptoms such as fatigue, hypersomnolence and cognitive impairment. The aim of this paper is to present the potential clinical applications of modafinil in the treatment of selected mental disorders. The use of modafinil in depressive disorders to enhance the treatment applied may improve mood, anhedonia and apathy, fatigue, hypersomnolence and executive cognitive impairment. In severe episodes of bipolar depression, modafinil may improve depressive symptoms, fatigue, and hypersomnia. Despite the potential risk of manic symptoms during modafinil treatment, recent studies show no increased risk of switching from depressive to manic phase. In schizophrenia, there is no evidence for the beneficial effect of modafinil on the negative symptoms, but improvement in selected cognitive functions accompanied by exacerbation of psychotic symptoms was observed in some patients. Furthermore, modafinil is used as an alternative to standard therapy in attention-deficit/hyperactivity disorder. Despite lacking evidence for the efficacy of modafinil in cocaine addiction, an analysis of selected studies indicates a potential benefit in the form of maintained abstinence. Modafinil is well tolerated and safe in most cases. The risk of dependence is lower than with other psychostimulants.

scholarly journals Bipolar Depression and Cognitive Impairment

2016 ◽  
Vol 39 (1) ◽  
pp. 95-109 ◽  
Author(s):  
Colin A. Depp ◽  
Sheena Dev ◽  
Lisa T. Eyler
Keyword(s):  
Cognitive Impairment ◽  
Bipolar Depression

“Subcortical” cognitive impairment in patients with systemic lupus erythematosus

2000 ◽  
Vol 6 (7) ◽  
pp. 821-825 ◽  
Author(s):  
ELIZABETH LERITZ ◽  
JASON BRANDT ◽  
MELISSA MINOR ◽  
FRANCES REIS-JENSEN ◽  
MICHELLE PETRI
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cognitive Impairment ◽  
Lupus Erythematosus ◽  
Systemic Lupus

Toward Identifying Mild Cognitive Impairment in Hispanic and African American Adults

2017 ◽  
Vol 2 (2) ◽  
pp. 110-116
Author(s):  
Valarie B. Fleming ◽  
Joyce L. Harris
Keyword(s):  
Older Adults ◽  
African American ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Healthcare Access ◽  
Communication Disorders ◽  
Healthcare Systems ◽  
Prevention Education ◽  
Education Management ◽  
African American Adults

Across the breadth of acquired neurogenic communication disorders, mild cognitive impairment (MCI) may go undetected, underreported, and untreated. In addition to stigma and distrust of healthcare systems, other barriers contribute to decreased identification, healthcare access, and service utilization for Hispanic and African American adults with MCI. Speech-language pathologists (SLPs) have significant roles in prevention, education, management, and support of older adults, the population must susceptible to MCI.

Sign in / Sign up

Export Citation Format

Share Document